CYTOKINE ADSORBER IN SEPSIS ASSOCIATED AKI

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

Abstract Title *

CYTOKINE ADSORBER IN SEPSIS ASSOCIATED AKI

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Sudheer Pandey sudhirp947@gmail.com Marengo Asia hospital Nephrology Faridabad India *

Co-author 2

Ambika Sharma ambikasharma305@gmail.com Marengo asia hospital Nephrology Faridabad India -

Co-author 3

Sidharth Yadav sidharthnephro@gmail.com Marengo asia hospital Nephrology Faridabad India -

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Sepsis-associated AKI (SA-AKI) is a major cause of ICU mortality. Cytokine adsorption with CytoSorb® during CRRT may help reduce the inflammatory load and stabilize hemodynamic. We compared outcomes in patients treated with CRRT ± CytoSorb®.

Methods

Retrospective study (Jan 2024 – Sep 2025) including 52 ICU patients with SA-AKI requiring CRRT.

Group A (n=22): CRRT + CytoSorb® & Group B (n=30): CRRT alone.

Variables: SOFA score, vasopressor dose, lactate, urine output, RRT independence, 28-day mortality were analysed. All patient received standard sepsis care as per surviving sepsis campaign guideline’s

Results

Both group were comparable in age, sex, infection source, and illness severity

Parameter	Group A	Group B	P-Value
↓ NE dose (%)	61 ± 20	33 ±25	0.02
↓ Lactate (mmol/L)	4à1.8	3.9à3	0.03
Urine (ml/Day)	850à 1650	870à1180	0.04
RRT free by day 7	45	27	0.11
SOFA(imorovement)	2.6 ±1.2	1.1 ±0.8	0.01
28-day mortality(%)	41	57	0.19

Conclusion

CytoSorb® use with CRRT in SA-AKI improved hemodynamic stability, lactate clearance, and urine output, with a trend toward better renal recovery and survival.Though the mortality difference was not statistically significant, early integration may optimize outcomes in severe sepsis. Larger multicentre studies warranted to confirm these findings and refine patient selection criteria in Indian ICUs

Kewords